Work

Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2575

Authors: Veronica Conca, Michelle Ting-Lin, Roberto Moretto, Xifeng Wang, Matteo Landi, Francesca Bergamo, Vittorio Studiale, Seung Won Hyun, Anna Chiaramonte, Ada Taravella, Ilaria Toma, Chithra Sangli, Carlotta Antoniotti, Maria Alessandra Calegari, Sabina Murgioni, John M. Abran, Federica Manoni, Stefano Tamberi, Halla Nimeiri, Chiara Cremolini

Institutions: University of Pisa, Azienda Ospedaliera Universitaria Pisana, Tempus Labs (United States), Istituto Oncologico Veneto, Fondazione IRCCS Istituto Nazionale dei Tumori, Agostino Gemelli University Polyclinic, University of Bologna

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Tempus

OpenAlex ID: W7162496007

Cites:

Cited by:

Related to: